Belimumab (Benlysta) — Coverage Criteria for Systemic Lupus Erythematosus and Lupus Nephritis
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage, prior authorization requirements, and limits for belimumab (Benlysta) for treatment of systemic lupus erythematosus and active lupus nephritis in members age 5 and older under BlueCross BlueShield of Tennessee.
No material clinical or coverage changes in this revision.
Coverage Criteria for Belimumab (Benlysta)
Systemic Lupus Erythematosus (Initial therapy)
Covered when ALL of the following are met
Examples: glucocorticoids, hydroxychloroquine, azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide
Active Lupus Nephritis (Initial therapy)
Covered when ALL of the following are met
Continuation of Therapy
Covered when ALL of the following are met
Authorization of 12 months may be granted
Use of belimumab (Benlysta) in combination with other biologic therapies is an exclusion to coverage. Additionally, initiation of belimumab is not permitted for members with severe active central nervous system (CNS) lupus, which includes seizures attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis that require therapeutic intervention prior to starting belimumab. These situations may trigger denial of coverage.
All indications for belimumab beyond the FDA-approved and recognized compendial uses are considered experimental/investigational and not medically necessary and therefore are not covered under this policy.
Dosing and Coding
| intravenous dosing regimen | Initial: 10 mg/kg every 2 weeks for 3 doses; Maintenance: 10 mg/kg every 4 weeks |
Prior Authorization, Documentation, and Provider Requirements
Prior Authorization Required
Prior authorization required for initial and continuation requests. Initial requests must include documentation of appropriate standard therapy for SLE or lupus nephritis and objective proof of relevant autoantibodies or kidney biopsy when applicable. Continuation requests must include medical records documenting disease stability or improvement.
- Authorization may be granted for up to 12 months for SLE or active lupus nephritis in members ≥5 years when criteria are met.
- Initial requests: medical records (chart notes, lab reports) showing autoantibodies relevant to SLE (e.g., ANA by IFA ≥1:80, anti-dsDNA, anti-Sm, antiphospholipid antibodies, low complement) or kidney biopsy confirming lupus nephritis where applicable.
- Continuation requests: medical records documenting disease stability or improvement.
Step / Adjunct Therapy Requirement
Member must be receiving standard SLE or lupus nephritis therapy prior to authorization. Examples include glucocorticoids, antimalarials, and immunosuppressants.
- SLE standard therapies: glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone), antimalarials (e.g., hydroxychloroquine), immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide).
- Lupus nephritis standard therapies: cyclophosphamide, mycophenolate mofetil, azathioprine, hydroxychloroquine, glucocorticoids.
Required Documentation
Documentation required to initiate prior authorization review: provide medical records (chart notes, laboratory reports) that demonstrate presence of autoantibodies relevant to SLE or a kidney biopsy supporting lupus nephritis when applicable. For continuation, provide records showing disease stability or improvement.
- Autoantibodies: ANA by IFA ≥1:80, anti-dsDNA, anti‑Smith (anti‑Sm), antiphospholipid antibodies, low complement proteins.
- If kidney biopsy performed: include pathology report confirming lupus nephritis.
- Continuation requests: recent clinical notes and labs documenting response, stability, or improvement.
Exclusion Triggers
Coverage exclusions that may trigger denial: use in combination with other biologics and initiation in members with severe active CNS lupus.
- Do not authorize if member is using Benlysta in combination with other biologic agents.
- Do not authorize initiation in members with severe active CNS lupus (e.g., seizures attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis requiring therapeutic intervention prior to belimumab initiation).
Background
Belimumab (Benlysta) is indicated for the treatment of active systemic lupus erythematosus (SLE) and active lupus nephritis in patients 5 years of age and older when used in combination with standard therapy. The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system (CNS) lupus, and use is not recommended in that population. Coverage exclusions include use in combination with other biologics and initiation of therapy in members with severe active CNS lupus (for example, seizures attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis requiring intervention prior to belimumab).
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.